Table 2.
Comparisons of causes of infertility and preimplantation genetic screening indications between two luteal phase support regimes
| Daily IMP (n = 573) | Daily VP plus IMHPC (n = 158) | p value | |
|---|---|---|---|
| Causes of infertility | 0.164 | ||
| Tubal factor | 87 (15.2) | 24 (15.2) | |
| Ovulatory dysfunction | 26 (4.5) | 12 (7.6) | |
| Diminished ovarian reserve | 91 (15.9) | 17 (10.8) | |
| Endometrioma | 16 (2.8) | 2 (1.3) | |
| Male factor | 61 (10.6) | 23 (14.6) | |
| Both couple | 142 (24.9) | 30 (18.9) | |
| More than one female factor | 42 (7.3) | 13 (8.2) | |
| Unexplained | 108 (18.8) | 37 (23.4) | |
| PGT-A indications | 0.171 | ||
| Advanced age (≥ 35 years) | 217 (37.9) | 53 (33.5) | |
| Recurrent implantation failure | 74 (12.9) | 12 (7.6) | |
| Recurrent pregnancy loss | 32 (5.6) | 6 (3.8) | |
| Chromosomal aberrations | 13 (2.3) | 4 (2.5) | |
| Single-gene carriers | 4 (0.7) | 1 (0.6) | |
| Patient request | 105 (18.3) | 32 (20.4) | |
| More than one indication | 128 (22.3) | 50 (31.6) | |
Data are given as number (percentage). IMP, VP, and IMHPC denote intramuscular progesterone, vaginal progesterone, and intramuscular hydroxyprogesterone caproate
PGT-A preimplantation genetic testing for aneuploidy